Skip to main content
All lobbying filings

THE UNITED STATES PHARMACOPEIAL CONVENTION

Lobbying for THE UNITED STATES PHARMACOPEIAL CONVENTION

 Filing 1st Quarter - Amendment
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Jul 20, 2026
Expenses
$130,000.00
What this organization spent lobbying with its own staff. Reported using B: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Maryland

Official filing document

 Government bodies contacted 2
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 3
 Lobbying activity 2
Health Issues

S. 1784 - Mapping America's Pharmaceutical Supply (MAPS) Act; H.R. 4191: Provisions regarding supply chain security and resilience and drug shortages. S. 3788 - Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act (CLEAR LABELS) Act: Provisions regarding drug labeling.

Budget/Appropriations

Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027: Provisions related to Administration for Strategic Preparedness and Response (ASPR) mapping. FY 2027 Commerce, Justice, Science, and Related Agencies Appropriations: Provisions related to 3D-printing. FY 2027 State-Foreign Operations Appropriations: Provisions related to pharmaceutical supply chain resilience.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem